kpt-8602
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 14, 2023 (NCT05918055)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Exportin-1INHIBITOR
XPO1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06399640 | Phase 1 | Aug 14, 2024 | Karyopharm Therapeutics Inc, National Cancer Institute (NCI), Vanderbilt University |
| NCT05918055 | Phase 1/Phase 2 (Phase 2) | Nov 14, 2023 | National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 2 | 2023 |
| Karyopharm Therapeutics Inc | For profit | 1 | 0 | 1 | 2024 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1